Drug Type Exosomes |
Synonyms Signal regulatory protein alpha (SIRPalpha)-Exosome, SBI 102, SBI102 |
Target |
Action modulators |
Mechanism SIRPα modulators(Signal-regulatory protein alpha modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute-On-Chronic Liver Failure | Preclinical | South Korea | 01 Feb 2024 | |
| Hepatitis, Alcoholic | Preclinical | South Korea | 01 Feb 2024 | |
| Idiopathic Pulmonary Fibrosis | Preclinical | South Korea | 01 Feb 2024 | |
| Liver Failure, Acute | Preclinical | United States | 01 Feb 2024 | |
| Metabolic Dysfunction Associated Steatohepatitis | Preclinical | South Korea | 01 Feb 2024 | |
| Metastatic Microsatellite Stable Colorectal Carcinoma | Preclinical | South Korea | 01 Feb 2024 | |
| Pulmonary Arterial Hypertension | Preclinical | South Korea | 01 Feb 2024 |





